Want to see JP:4882 full AI Analyst Report?
Perseus Proteomics, Inc. (4882) AI Stock Analysis
Perseus Proteomics, Inc.
(TSE/TYO:4882)
The overall score is heavily pressured by the company's weak financial performance, marked by significant and ongoing net losses and negative cash flows, despite a debt-free balance sheet. The negative P/E ratio further underscores the lack of profitability. Short-term technical momentum provides a slight positive counterbalance, but the stock remains in a longer-term downtrend.
Perseus Proteomics, Inc. (4882) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 2.62B
- Dividend Yield
- ―
- Average Volume (3M)
- 464.53K
- Price to Earnings (P/E)
- -3.0
- Beta (1Y)
- 1.62
- Revenue Growth
- 19.70%
- EPS Growth
- 17.73%
- Country
- Japan
- Employees
- 35
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - General
Perseus Proteomics, Inc. Business Overview & Revenue Model
Company Description
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alo...
How the Company Makes Money
null
Perseus Proteomics, Inc. Financial Statement Overview
Summary
Revenue is growing and the balance sheet is debt-free, but the company is deeply unprofitable with net losses exceeding revenue and negative cash flows. The overall financial health is poor, driven by the Income Statement (30) and Cash Flow (25) scores, only partially offset by a moderate Balance Sheet (55).
Income Statement
30NegativeBalance Sheet
55NeutralCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 147.22M | 135.51M | 120.38M | 100.40M | 94.20M | 71.93M |
| Gross Profit | 126.49M | 116.16M | 104.05M | 87.69M | 86.53M | 67.75M |
| EBITDA | -744.74M | -715.80M | -899.49M | -1.10B | -779.36M | -594.14M |
| Net Income | -744.64M | -718.11M | -904.80M | -1.10B | -787.00M | -599.02M |
Balance Sheet | ||||||
| Total Assets | 1.67B | 1.62B | 1.82B | 1.69B | 2.57B | 3.30B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 1.52B | 1.67B | 1.54B | 2.44B | 3.21B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 442.44M | 405.77M | 386.43M | 295.46M | 170.10M | 148.38M |
| Stockholders Equity | 1.22B | 1.22B | 1.43B | 1.40B | 2.40B | 3.15B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -662.83M | -794.64M | -976.90M | -734.82M | -510.71M |
| Operating Cash Flow | 0 | -653.33M | -719.49M | -833.90M | -564.27M | -476.84M |
| Investing Cash Flow | 0 | -10.06M | -75.16M | -150.34M | -212.99M | -33.87M |
| Financing Cash Flow | 0 | 497.33M | 923.38M | 63.94M | -20.00K | 2.65B |
Perseus Proteomics, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4882, the sentiment is Negative. The current price of 142.00 is below the 20-day moving average (MA) of 149.00, below the 50-day MA of 154.32, and below the 200-day MA of 188.00, indicating a bearish trend. The MACD of -5.17 indicates Positive momentum. The RSI at 41.79 is Neutral, neither overbought nor oversold. The STOCH value of 49.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4882.
Perseus Proteomics, Inc. Peers Comparison
Overall Rating
JP:609073Outperform
JP:338669.4Neutral
JP:770761Neutral
JP:234250Neutral
JP:497842Neutral- JP:488242Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:6090 | 73Outperform | JPY 3.50B | 16.32 | ― | 3.05% | -2.27% | -17.23% |
| JP:3386 | 69Neutral | JPY 7.16B | 19.27 | ― | 4.05% | 9.39% | 44.42% |
| JP:7707 | 61Neutral | JPY 5.59B | 14.02 | ― | 0.99% | 11.17% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:2342 | 50Neutral | JPY 3.63B | 112.09 | ― | ― | 2.37% | ― |
| JP:4978 | 42Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:4882 | 42Neutral | JPY 2.62B | -2.95 | ― | ― | 19.70% | 17.73% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4882 | Perseus Proteomics, Inc. | 142.00 | -154.00 | -52.03% | |
| JP:2342 | Trans Genic Inc. | 215.00 | 24.00 | 12.57% | |
| JP:3386 | Cosmo Bio Co., Ltd. | 1236.00 | 135.82 | 12.34% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:6090 | Human Metabolome Technologies, Inc. | 591.00 | -94.92 | -13.84% | |
| JP:7707 | Precision System Science Co.,Ltd | 202.00 | 17.00 | 9.19% |
Perseus Proteomics, Inc. Corporate Events
Perseus Proteomics Flags FX Gains, Financing Costs and Asset Impairment in Q2 Results
Perseus Proteomics Inc. reported several non-operating and extraordinary items in its non-consolidated financial results for the quarter ended June 30, 2026. The biotech firm’s disclosure highlights movements in foreign exchange, financing-rela...
Perseus Proteomics Narrows Loss as Sales Rise but Withholds Full-Year Outlook
Perseus Proteomics Inc. reported non-consolidated results for the quarter ended June 30, 2026, showing net sales of ¥35 million, up 49.9% year on year but still posting an operating loss of ¥204 million and a net loss of ¥202 million....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 09, 2026